This work are devoted our experience with photodynamic therapy (PDT) with <<Photosens>> for patients
with choroidal neovascularization (CNV). 18 patients with subfoveal CNV in age-related macular degeneration
(AMD), 24 patients with subfoveal CNV in pathological myopia (PM) and 4 patients with subfoveal CNV
associated with toxoplasmic retinochoroiditis were observed. CNV was 100% classic in all study patients.
Standardized protocol refraction, visual acuity testing, ophthalmologic examinations, biomicroscopy, fluorescein
angiography, and ultrasonography were performed before treatment and 1 month, 3 months, 6 months, and 1 year
after treatment; were used to evaluate the results of photodynamic therapy with <<Photosens>> (0.02% solution of
mixture sulfonated aluminium phtalocyanine 0.05 mg/kg, intravenously). A diode laser (<<Biospec>>, Inc, Moscow)
was used operating in the range of 675 nm. Need for retreatment was based on fluorescein angiographic evidence of
leakage at 3-month follow-up intervals.
At 3, 6, 9 month 26 (56.5%) patients had significant improvement in the mean visual acuity. At the end of
the 12-month minimal fluorescein leakage from choroidal neovascularization was seen in 12 (26.1%) patients and
the mean visual acuity was slightly worse than 0.2 which was not statistically significant as compared with the
baseline visual acuity. Patients with fluorescein leakage from CNV underwent repeated PDT with <<Photosens>>. 3D-mode
ultrasound shown the decreasing thickness of chorioretinal complex in CNV area.
Photodynamic therapy with <<Photosens>> can safely reduce the risk of severe vision loss in patients with
predominantly classic subfoveal choroidal neovascularization secondary to AMD, PM and toxoplasmic